key: cord-1032088-wfx0egqk
authors: Louca, Stilianos
title: SARS-CoV-2 infections in 165 countries over time
date: 2021-09-03
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.08.067
sha: be5db464e1096b903feb1c32125d85ac70bae43e
doc_id: 1032088
cord_uid: wfx0egqk

Background: Understanding the dynamics of the COVID-19 pandemic and evaluating the efficacy of control measures requires knowledge of the number of infections over time. This number, however, often differs from the number of confirmed cases due to a large fraction of asymptomatic infections and variable testing strategies. Methods: This study uses death count statistics, age-dependent infection fatality risks and stochastic modeling to estimate the prevalence of SARS-CoV-2 infections among adults (age [Formula: see text] years) in 165 countries over time, from early 2020 until June 25, 2021. The accuracy of the approach is confirmed through comparison to previous nationwide seroprevalence surveys. Results: The presented estimates reveal that the fraction of infections that are detected vary widely over time and between countries, and hence confirmed cases alone often yield a false picture of the pandemic. As of June 25, 2021, the nationwide cumulative fraction of SARS-CoV-2 infections (cumulative infections relative to population size) is estimated at 98% (95%-CI 93–100) for Peru, 83% (61–94) for Brazil and 36% (23–61) for the US. Conclusions: The presented time-resolved estimates expand the possibilities to study the factors that influenced and still influence the pandemic’s progression in 165 countries.

undoubtedly be the topic of scholarly work for years to come. Due to the existence of a large fraction 28 of asymptomatic cases as well as variation in reporting, testing effort and testing strategies (e.g., 29 random vs symptom-triggered) (Chow et al., 2020) , reported case counts cannot be directly con-30 verted to infection counts and a comparison of confirmed case counts between countries is generally 31 of limited informative value (Lachmann et al., 2020) . Large-scale seroprevalence surveys (e.g., us-32 ing antibody tests) can yield information on the disease's prevalence and cumulative number of 33 infections in a population, either directly or using dynamical modeling (Larremore et al., 2021) . 34 However, such surveys involve substantial financial and logistical challenges, and only yield reli- ture as well as the disease's age distribution (Dowd et al., 2020) . Indeed, it was shown that the 47 age-dependency of the IFR, the age-dependency of SARS-CoV-2 prevalence, and the age structure 48 of the population are largely sufficient to explain variation in the effective IFR between countries 49 (Levin et al., 2020) . This suggests that age-stratified death counts (or estimates thereof) should be 50 used in conjunction with age-dependent IFRs in order to obtain an accurate estimate of infection 51 counts. This approach has been successfully used to estimate SARS-CoV-2 prevalence over time in 52 Europe until May 4, 2020, based on reported age-stratified death counts (Flaxman et al., 2020) . In 53 principle, one could also first determine the "effective" (integrated over all ages) IFR for the entire 54 population and combine that effective IFR with total (non-age-stratified) death counts to estimate 55 infection rates. This approach was taken by Sánchez-Romero et al. (2021) , who first estimated the 56 effective IFR for various states in the US based -among others -on age-specific mortality data 57 and then estimated the cumulative number of SARS-CoV-2 infections across the US as of Septem-58 ber 8, 2020. However, such an effective IFR is specific to the population for which it was estimated, 59 and hence applying it to other countries (even if correcting for the local population age structure, This study addresses the above challenges by leveraging information on the age distribution of 80 SARS-CoV-2 infections from multiple countries with available age-stratified death reports, to es-81 timate the likely age-distribution of SARS-CoV-2 in other countries, while accounting for each 82 country's population age structure and for uncertainty due to additional unidentified factors. Based 83 on these calibrations, national SARS-CoV-2 prevalences (cumulative number of infections, weekly 84 new infections and exponential growth rate) are estimated over time, while accounting for each 85 country's population age structure, the likely age distribution of infections, the age dependency 86 of the IFR, and variation in the time lag between infection and death. The estimates are specific 87 to adults aged 20 years or more, covering 165 countries from early 2020 until June 25, 2021. The one age group relative to any other age group) are needed. To determine the general distribution of 98 age-specific infection risk ratios, this study analysed weekly age-stratified COVID-19-related death 99 reports from 15 countries around the world using a probabilistic model of Poisson-distributed time-100 delayed death counts (see Methods for details). Briefly, for any given country c, any given week w, 101 and any given age group g, the number of new infections during that week (I c,w,g ) is assumed to 102 be approximately equal to α c,g I c,w,r N c,g /N c,r , where r represents some fixed reference age group, 103 N c,g is the population size of age group g, and α c,g is the relative risk of an individual in age group 104 g being infected compared to that of an individual in age group r. The expected number of deaths 105 in each age group 4 weeks later (roughly the average time lag between infection and death (Linton 106 et al., 2020)), denoted D c,w+4,g , was assumed to be I c,w,g R g , where R g is the IFR for that age group.

Note that while R g could in principle also vary between countries, to date insufficient information 108 is available for calibrating R g separately for each country (but see discussion of caveats below). for the age-structure of each country, the age-distribution of the disease in each country and the age-113 dependency of the IFR. A critical assumption of the model is that, in any given country, nationwide 114 age-specific infection risks co-vary linearly between age groups over time, i.e., an increase of dis-115 ease prevalence in one age group coincides with a proportional increase of prevalence in any other 116 age group. This assumption is motivated by the observation that weekly nationwide death counts 117 generally covary strongly linearly between age groups ( Fig. 1A and Supplemental Figs. S1 and 118 S2); the adequacy of this model is also confirmed in retrospect (see below). For each country, the 119 infection risk ratios α c,g (for all g = r) and the weekly infections in the reference age-group I c,w,r 120 (one per week) were fitted to the age-stratified weekly death counts using a maximum-likelihood ap-121 proach and assuming that weekly death counts follow a Poisson distribution. This stochastic model 122 explained the data generally well, with observed weekly death counts almost always falling within 123 the 95% confidence interval of the model's predictions (Supplemental Fig. S3 ). This supports the 124 initial assumption that infection risks co-vary approximately linearly between age groups over time 125 and suggests that country-specific but time-independent infection risk ratios are largely sufficient 126 for describing the age-distribution of SARS-CoV-2 infections in a country and over time. For any 127 given age group g, the fitted infection risk ratios α c,g differed between countries but were generally 128 within the same order of magnitude (Fig. 1B) . On the basis of this observation, and as explained in 129 the next section, it thus seems possible to approximately estimate the number of infections in any 130 other country based on total death counts, the population's age structure and the pool of infection 131 risk ratios α c,g fitted above (accounting for the uncertainty in the latter due to unknown additional 132 factors). 2 0 -2 4 2 5 -2 9 3 0 -3 4 3 5 -3 9 4 0 -4 4 4 5 -4 9 5 0 -5 4 5 5 -5 9 6 0 -6 4 6 5 -6 9 7 0 -7 4 7 5 -7 9 8 0 -8 4 8 5 -8 9 9 0 -9 4 9 5 -9 9 1 0 0 + age group infection risk ratio B A weekly deaths in age group 50-54 weekly deaths in age group 70-74 relative age-specific infection risks death counts (US) Figure 1 : Infection and death rates covary linearly between age-groups. (A) Weekly reported COVID-19-related death counts in the US, in age group 70-74 (horizontal axis) and age group 50-54 (vertical axis). Each point corresponds to a different week (defined here as a 7-day period). The linear regression line is shown for reference. For additional age groups and countries see Supplemental Fig. S1 . The strong co-linearity of death rates between age-groups suggests that infection risks also covary linearly between agegroups. (B) Relative infection risks (relative to age group 70-74) for different countries, estimated based on death-stratified COVID-19-related death counts. Each column represents a different age group, and in each column each point represents a distinct country. Horizontal bars represent medians and boxes span 50%-percentiles of the data. 134 Based on the pool of fitted infection risk ratios, the same age-dependent IFRs used above, the 135 probability distribution of time lags between infection, disease onset and death (Linton et al., 2020) , 136 and total (non-age-stratified) COVID-19-related death count reports disseminated by the WHO, the 137 weekly infection counts were estimated over time in each of 165 countries that met certain data 138 quality criteria (details in Methods). Briefly, for any given country c, week w and any given set of 139 relative infection risks α 1 , α 2 , .., the total number of deaths during that week (D c,w ) was assumed 140 to be Poisson-distributed with expectation equal to:

where as before R g is the IFR for age group g, N c,g is the population size of age group g, δ k is 142 the probability that a fatal infection will result in death after k weeks, L min and L max are the min- analysis or medical imaging (Mendel, 1990; Wiener, 1964) . Put simply, deconvolution can be in- suggest concrete steps to eliminate these discrepancies or correct for them.

The above observations imply that comparisons of the epidemic's extent and progression between Table S1 ). (P-T) Estimated exponential growth rate based on weekly infection counts, for the same countries as in A-E. Horizontal axes are shown for reference. Each column shows estimates for a different country. All model estimates refer to adults aged ≥20 years, while reported cases (blue curves) refer to the entire population. Analogous plots for all 165 investigated countries are provided as Supplemental File 6. Table S2 ).

Calibrating age-specific infection risk ratios 369 The age-specific infection risk ratios were calibrated as follows. Age-specific population sizes ity (the largest decrease of cumulative deaths between any two time points for any considered age 381 group) was greater than 1% of the maximum reported total cumulative deaths in that country (for 382 example Canada) was omitted. For similar reasons, countries for which an interpolation was needed 383 (either due to missing data, or due to a violation of monotonicity) in any considered age group over 384 a time span greater than 5 weeks (for example Iceland) was also omitted. 

For each considered country c, the "reference" age group r was set to the age group that had the 396 highest cumulative number of deaths. Designating a reference group is done purely for notational 397 simplicity and consistency, so that age-specific prevalence ratios can all be defined relative to a 398 common reference. For each other age group g, the infection risk ratio α c,g , i.e., the probability of 399 an individual in group g being infected relative to the probability of an individual in group r being 400 infected, was estimated using a probabilistic model. According to this model, the number of deaths 401 in group g during week w (denoted D c,w,g ) was Poisson distributed with expectation:

(

Here, N c,g is the population size of age group g in country c and R g is the IFR for age group g. 403 Under this model, the maximum-likelihood estimate for α c,g , i.e. given the weekly death count 404 time series, is given by: Fig. S12 ). Note that α c,g might also alternatively be estimated as the slope of the 411 linear regression:

Estimates obtained via linear regression were nearly identical to those obtained using the aforemen- 

To evaluate the adequacy of the above stochastic model in explaining the original death count data, 420 multiple hypothetical weekly death counts were simulated for each age group, and the distribution 421 of simulated death counts was compared to the true death counts. Specifically, for each country c, 422 week w and age group g, 100 random death counts (D c,w,g ) were drawn from a Poisson distribution 

In the subsequent analyses, only infection risk ratios α c,g for which the corresponding linear curve 429 (Eq. 5) achieved a coefficient of determination (R 2 ) greater than 0.5 were used (shown in Fig. 1 case counts were made non-decreasing and interpolated onto a weekly time grid as described above.

Only countries that reported at least one death per week for at least 10 weeks were included in the 441 analysis below. In addition, any country for which the strongest violation in monotonicity was 442 greater than 1% of the maximum reported total cumulative deaths in that country, or for which an 443 interpolation was needed (e.g., due to missing data) over a time span greater than 5 weeks (as done D c,w,g , was assumed to be Poisson-distributed with expectation equal to:

The total number of deaths in week w, D c,w , is thus Poisson-distributed with expectation: plemental Table S3 ). The minimum and maximum considered lags were L min = 2 and L max = 6 462 weeks, since this range covers the bulk (∼90%) of cases, and since further increasing L max or de- preceding weeks. (Mendel, 1990; Wiener, 1964) . Eq. (10) can be written abstractly in matrix form:

where K is a convolution matrix of size N × (N + L − 1): 

In principle, one could estimate the unknown vector I via maximum-likelihood. Indeed, the above 478 log-likelihood is maximized when the following condition is met: 

The corresponding-maximum likelihood estimateĴ can no longer be obtained simply by solving 

The corresponding cumulative number of total infections up until any given week can be obtained 509 by summing the weekly infection counts.

Exponential growth rates over time were estimated from the weekly infection counts using a sliding-window approach, as follows. In every sliding window (spanning 5 consecutive weeks), 512 an exponential function of the form I(t) = Ae tλ was fitted, where t denotes time in days and A 513 and λ are unknown parameters (in particular, λ is the exponential growth rate in that window).

The parameters A and λ were fitted via maximum likelihood, assuming that the total number of 515 weekly infections, I c,w , was Poisson distributed with expectation Ae twλ . Under this model, the 516 log-likelihood of the data (more precisely, of the previously estimated weekly infection counts) is:

where w iterates over all weeks in the specific sliding window. The maximum-likelihood estimates Files 1-5. A comprehensive visual report for all 165 countries is provided as Supplemental File 6.

Competing interests 559 The authors declare that they have no competing interests.

The author was supported by a US National Science Foundation RAPID grant.

Authors' contributions 563 The entire manuscript was prepared by S.L.

The authors declare that they have no known competing financial interests or personal relationships 746 that could have appeared to influence the work reported in this paper.

Nationwide 568 seroprevalence of SARS-CoV-2 in Saudi Arabia

CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-571 sectional study

Estimating 573 and characterizing COVID-19 deaths

The first wave of the SARS-CoV-2 epidemic in

A SI2R2D compartmental model with uncertainty evaluation

The COVID-19 (SARS-CoV-2) uncer-578 tainty tripod in Brazil: Assessments on model-based predictions with large under-reporting

Excess mortality: the gold 581 standard in measuring the impact of COVID-19 worldwide?

ing the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-584 experimental study

Repeated 586 leftover serosurvey of SARS-CoV-2 IgG antibodies

A demographic scaling model for estimating the total num-589 ber of COVID-19 infections

SARS-CoV-2 seroprevalence 591 survey estimates are affected by anti-nucleocapsid antibody decline

Factors influencing 594 the efficacy of COVID-19 vaccines: A quantitative synthesis of phase III trials

Is India missing COVID-19 deaths?

Global prediction of unreported SARS-CoV2 infec-598 tion from observed COVID-19 cases

Covid-19 in italy: An analysis of death registry data

United Nations, 602 Department of Economic and Social Affairs, Population Division

Demographic science aids 604 in understanding the spread and fatality rates of COVID-19

Prevalence 607 of SARS-CoV-2 antibodies in Denmark 2020: results from nationwide, population-based sero-608 epidemiological surveys

Covid-19 death reporting inconsistencies and working lessons for 610 low-and middle-income countries: Opinion

Interim 612 estimates of covid-19 vaccine effectiveness in a mass vaccination setting: data from an italian 613 province

Estimating the effects 615 of non-pharmaceutical interventions on COVID-19 in Europe

COVID-19 in Brazil: how many are there and which are being identified?

A forensic analysis of SARS-CoV-2 cases and COVID-19 mortality 620 misreporting in the Brazilian population

Impact and effectiveness of 622 mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases

tions, and deaths following a nationwide vaccination campaign in Israel: an observational study 624 using national surveillance data

Remarkable variability 626 in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey 627 in 27 states

An interpretation of reported COVID-19 cases in post-Soviet states

Under-reporting of COVID-19 cases in Turkey

Excess mortality reveals COVID's true toll in Russia

Testing for SARS-CoV-2 (COVID-634 19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic as-635 says

Correcting under-reported COVID-19 case num-637 bers: estimating the true scale of the pandemic

SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological 640 surveys

Evaluating the massive 642 underreporting and undertesting of COVID-19 cases in multiple global epicenters

CoV-2 antibodies in France: results from nationwide serological surveillance

COVID-19: a need 648 for real-time monitoring of weekly excess deaths

Assess-650 ing the age specificity of infection fatality rates for COVID-19: Meta-analysis & public policy 651 implications

The foreshadow of 653 a second wave: An analysis of current COVID-19 fatalities in Germany

Incubation 655 period and other epidemiological characteristics of 2019 novel coronavirus infections with right 656 truncation: A statistical analysis of publicly available case data

Potential biases in es-658 timating absolute and relative case-fatality risks during outbreaks

Problems of data availability and quality for 661 covid-19 and older people in low-and middle-income countries

Clinical and immunological assessment 664 of asymptomatic SARS-CoV-2 infections

Microbial metabolite fluxes in a model 666 marine anoxic ecosystem

Estimating the cumulative 668 incidence of COVID-19 in the United States using four complementary approaches

A comparison of six deconvolution 671 techniques

Estimation of unreported novel coronavirus

CoV-2) infections from reported deaths: A susceptible-exposed-infectious-recovered-dead 674 model

Modeling the novel coronavirus (SARS-CoV-2) 676 outbreak in Sicily, Italy

Maximum-Likelihood Deconvolution

Novel coronavirus 679 epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit 680 policy in Hungary

On the reciprocal of the general algebraic matrix

Preva-683 lence of SARS-CoV-2 infection in India: Findings from the national serosurvey

findings from the second 687 nationwide household serosurvey

Nationwide seroprevalence of antibodies to SARS-689

CoV-2 in asymptomatic population in South Korea: a cross-sectional study

COVID-19 cases in India and Kerala: a Benford's law analysis

Why is the number of COVID-19 cases lower than expected in Sub-694

Saharan Africa? A cross-sectional analysis of the role of demographic and geographic factors

Age-697 specific mortality and immunity patterns of SARS-CoV-2

Covid-19 and nigeria: putting the realities in context

Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide 702 seroepidemiological study

Accurate statistics on COVID-19 are 704 essential for policy guidance and decisions

A generalized inverse for matrices

Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two 708 rounds of a nationwide population study on a probability-based sample, challenges and lessons 709 learned

Preva-711 lence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemio-712 logical study

Nationwide 714 seroprevalence of antibodies against SARS-CoV-2 in Israel

Data resource profile: COVerAGE-DB: a global 716 demographic database of COVID-19 cases and deaths

An empirical estimate of the infection fatality rate of COVID-19 from the 718 first Italian outbreak

Estimating the burden 720 of SARS-CoV-2 in France

An indirect method to monitor the 722 fraction of people ever infected with COVID-19: An application to the United States

International comparisons of COVID-19 deaths in the presence of comorbidities require 725 uniform mortality coding guidelines

Prevalence 727 of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study

Efficacy and safety of COVID-19 vaccines in older people

Real world effectiveness 732 of COVID-19 mRNA vaccines against hospitalizations and deaths in the United States

Covid-19 mortality underreporting in brazil: 736 Analysis of data from government internet portals

Two constrained deconvolution methods using spline functions

Antibody prevalence 740 for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 741 adults

Extrapolation, Interpolation, and Smoothing of Stationary Time Series

Not applicable. 566